Xenon Pharmaceuticals Inc.’s Post

This month we’ve celebrated our 5th anniversary at Dewpoint. Our CEO, Ameet Nathwani shares his perspectives on the astounding progress our team has made, having taken the theoretical ideas of biomolecular condensates and transformed them into tangible science with the potential to create a new class of medicines, condensate-modifying therapeutics (c-mods). Read his article on how Dewpoint is gearing up to meet our goals to start the next revolution in medicine https://lnkd.in/eeCFFNai.

If you or anyone you know is looking for some lab space to jumpstart your research, please reach out! ABI Lab is the place to be ✨ If you don’t believe me, check out this most recent news letter by MetroWest Daily News!

We have officially dosed our first patient in the Zucara Therapeutics Inc. ZONE study. Grateful to be able to do such groundbreaking work for the #Type1Diabetes community as we attempt to eliminate #hypoglycemia. Dr. Alex Abitbol, who previously evaluated ZT-01 in a Phase 1b study and will be a principal investigator for ZONE, commented, "The positive results from the proof-of-concept Phase 1b study of ZT-01 were intriguing: in addition to observing a rise in glucagon, we also saw a corresponding rise in glucose during hypoglycemia. This suggests that ZT-01 can prevent nocturnal hypoglycemia, which is what we aim to confirm in the ZONE trial." Read more about this landmark study here: https://lnkd.in/gN48gNr5 #clinicalresearch #clinicaltrials #revolutionizingresearch

Macrocyclic drugs seem to be an area getting investment dollars these days -- Circle Pharma, Inc., a #UCSF - #UCSantaCruz spinoff with QB3 roots, just raised $54 million as part of a Series D. Circle is developing cyclin inhibitors for solid tumors. As mentioned in this Endpoints News story, Vilya, Orbis Medicines, and Bakar Labs tenant Insamo, all pursuing some form of macrocycles, all recently won funding. "Small molecule drugs can struggle with certain targets, such as the protein-protein interactions behind a wide range of diseases, including cancer. Antibodies, which boast that specificity, can’t be given as a pill. Macrocycles, however, can potentially bind very specific targets and they can be delivered in pill form." https://lnkd.in/dBk_adUB

Today marks a significant milestone as we received authorization to initiate a Phase 1 clinical trial in healthy volunteers for ENTR-601-44 in the United Kingdom. ENTR-601-44 is our lead product candidate within our Duchenne franchise. There exists a profound unmet medical need for people living with Duchenne who are exon 44 skipping amenable, and we look forward to this next stage of ENTR-601-44’s development.   This milestone, coupled with the extension of our cash runway through the end of 2025, positions Entrada to advance our Duchenne franchise while broadening the potential of our intracellular therapeutics across serious diseases. https://lnkd.in/eDHw4AFm   #Biotech #EntradaHere

4 relevant business insights from ASCO: 1- Lilly revamped in oncology: would be enough to diversify portfolio 2-Need of multi regional clinical trials, specially when thinking in Chinese developments 3- Amgen KRAS treatment in CRC 4- ADCs fails in clinical trials and future development

Exciting times ahead in the field of biotechnology! With regulatory bodies focusing on optimizing quality control processes and fostering an integrated ecosystem, we're set to witness significant advancements. The approval of commercial autologous products has de-risked the approach, paving the way for automation and innovation by instrument and equipment developers. In the coming years, our focus should shift towards enhancing efficiency in testing and release, marking the next frontier in this dynamic industry. #Biotech #Innovation #FutureOfBiotech

What is it like to live with thyroid eye disease (TED)? Viridian Therapeutics, Inc. is studying multiple candidates in clinical studies for TED, and recently met with a group of individuals living with TED to gain a deeper understanding about their lived experiences. The image below shares some of what the company learned about people's varied and individualized journeys with the disease. Learn more at https://lnkd.in/eZTGdQ9m #biotech #TED

Did you know that the ISOPP Engagement and Communications Committee’s objectives includes ensuring members are updated on information that is valuable & interesting to members’ professional development & experience in ISOPP, as well as news from the wider / global Oncology Pharmacy network, through newsletters, the website and social media. If you have any news items to share, we would love to hear from you at newsletter@isopp.org #ISOPP

Nice article. Many of you will see some very familiar names 😊